DOCSLIB.ORG

Kopi Af Aktivlisten 2021-06-30 Ny.Xlsm

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kopi Af Aktivlisten 2021-06-30 Ny.Xlsm Velliv noterede aktier i alt pr. 30-06-2021 ISIN Udstedelsesland Navn Markedsværdi (i DKK) US0378331005 US APPLE INC 1.677.392.695 US5949181045 US MICROSOFT CORP 1.463.792.732 US0231351067 US AMAZON.COM INC 1.383.643.996 DK0060534915 DK NOVO NORDISK A/S-B 1.195.448.146 US30303M1027 US FACEBOOK INC-CLASS A 1.169.094.867 US02079K3059 US ALPHABET INC-CL A 867.740.769 DK0010274414 DK DANSKE BANK A/S 761.684.457 DK0060079531 DK DSV PANALPINA A/S 629.313.827 US02079K1079 US ALPHABET INC-CL C 589.305.120 US90138F1021 US TWILIO INC - A 514.807.852 US57636Q1040 US MASTERCARD INC - A 490.766.560 US4781601046 US JOHNSON & JOHNSON 478.682.981 US70450Y1038 US PAYPAL HOLDINGS INC 471.592.728 DK0061539921 DK VESTAS WIND SYSTEMS A/S 441.187.698 US79466L3024 US SALESFORCE.COM INC 439.114.061 US01609W1027 US ALIBABA GROUP HOLDING-SP ADR 432.325.255 US8835561023 US THERMO FISHER SCIENTIFIC INC 430.036.612 US22788C1053 US CROWDSTRIKE HOLDINGS INC - A 400.408.622 KYG875721634 HK TENCENT HOLDINGS LTD 397.054.685 KR7005930003 KR SAMSUNG ELECTRONICS CO LTD 389.413.700 DK0060094928 DK ORSTED A/S 378.578.374 ES0109067019 ES AMADEUS IT GROUP SA 375.824.429 US46625H1005 US JPMORGAN CHASE & CO 375.282.618 US67066G1040 US NVIDIA CORP 357.034.119 US17275R1023 US CISCO SYSTEMS INC 348.160.692 DK0010244508 DK AP MOLLER-MAERSK A/S-B 339.783.859 US20030N1019 US COMCAST CORP-CLASS A 337.806.502 NL0010273215 NL ASML HOLDING NV 334.040.559 CH0012032048 CH ROCHE HOLDING AG-GENUSSCHEIN 325.008.200 KYG970081173 HK WUXI BIOLOGICS CAYMAN INC 321.300.236 US4370761029 US HOME DEPOT INC 317.083.124 US58933Y1055 US MERCK & CO. INC. 316.530.900 US91324P1021 US UNITEDHEALTH GROUP INC 311.374.980 GB00B2B0DG97 GB RELX PLC 307.988.970 US92826C8394 US VISA INC-CLASS A SHARES 306.291.447 US92343V1044 US VERIZON COMMUNICATIONS INC 304.765.853 US4523271090 US ILLUMINA INC 304.426.011 CH0038863350 CH NESTLE SA-REG 293.721.338 US7427181091 US PROCTER & GAMBLE CO/THE 293.333.160 KYG017191142 HK ALIBABA GROUP HOLDING LTD 290.520.579 US7134481081 US PEPSICO INC 289.677.804 US0846707026 US BERKSHIRE HATHAWAY INC-CL B 281.085.188 FR0000052292 FR HERMES INTERNATIONAL 272.359.543 FR0000121014 FR LVMH MOET HENNESSY LOUIS VUI 271.799.150 DE000A1EWWW0 DE ADIDAS AG 270.792.071 US00206R1023 US AT&T INC 270.523.087 US68389X1054 US ORACLE CORP 267.112.209 US1101221083 US BRISTOL-MYERS SQUIBB CO 264.077.569 US7170811035 US PFIZER INC 262.570.714 DK0010181759 DK CARLSBERG AS-B 261.399.752 FR0000130650 FR DASSAULT SYSTEMES SE 259.228.491 US0605051046 US BANK OF AMERICA CORP 258.650.949 DK0010272202 DK GENMAB A/S 255.417.566 CH0013841017 CH LONZA GROUP AG-REG 252.012.005 US2546871060 US WALT DISNEY CO/THE 247.719.432 ES0105066007 ES CELLNEX TELECOM SA 242.571.280 US00724F1012 US ADOBE INC 232.193.130 US81762P1021 US SERVICENOW INC 228.240.956 US1266501006 US CVS HEALTH CORP 220.624.711 TW0002330008 TW TAIWAN SEMICONDUCTOR MANUFAC 220.276.508 US4581401001 US INTEL CORP 213.069.674 US00287Y1091 US ABBVIE INC 206.931.610 CH0012005267 CH NOVARTIS AG-REG 202.931.724 DK0060448595 DK COLOPLAST-B 201.909.187 US87612E1064 US TARGET CORP 201.879.721 US2786421030 US EBAY INC 200.337.497 JP3735400008 JP NIPPON TELEGRAPH & TELEPHONE 199.358.059 FR0000120693 FR PERNOD RICARD SA 197.146.120 US30231G1022 US EXXON MOBIL CORP 196.315.337 US5324571083 US ELI LILLY & CO 195.042.252 CH0012100191 CH TECAN GROUP AG-REG 194.893.691 IE00BTN1Y115 US MEDTRONIC PLC 191.975.874 DK0010272632 DK GN STORE NORD A/S 189.616.854 FR0010908533 FR EDENRED 189.098.454 US8636671013 US STRYKER CORP 187.271.286 US1255231003 US CIGNA CORP 185.553.481 US0028241000 US ABBOTT LABORATORIES 184.136.336 DK0060252690 DK PANDORA A/S 179.993.137 US58733R1023 US MERCADOLIBRE INC 178.187.476 NL0012969182 NL ADYEN NV 176.307.280 US40415F1012 US HDFC BANK LTD-ADR 175.629.924 US4592001014 US INTL BUSINESS MACHINES CORP 175.076.873 IT0000072170 IT FINECOBANK SPA 173.560.656 US0311621009 US AMGEN INC 172.261.657 US64110L1061 US NETFLIX INC 168.876.223 NL0010801007 NL IMCD NV 168.652.806 HK0000069689 HK AIA GROUP LTD 165.558.040 US81141R1005 US SEA LTD-ADR 165.341.830 FR0000120578 FR SANOFI 163.606.016 US22160K1051 US COSTCO WHOLESALE CORP 162.314.043 DE0006231004 DE INFINEON TECHNOLOGIES AG 160.364.719 DK0060636678 DK TRYG A/S 156.467.458 US1912161007 US COCA-COLA CO/THE 154.770.856 US1729674242 US CITIGROUP INC 153.366.553 US1667641005 US CHEVRON CORP 153.344.569 GB00B10RZP78 GB UNILEVER PLC 153.002.636 US8825081040 US TEXAS INSTRUMENTS INC 151.453.346 US9311421039 US WALMART INC 151.162.620 US6536561086 US NICE LTD - SPON ADR 148.361.083 IE00B4BNMY34 US ACCENTURE PLC-CL A 148.155.544 CA7800871021 CA ROYAL BANK OF CANADA 148.022.707 JP3633400001 JP TOYOTA MOTOR CORP 148.012.487 US65339F1012 US NEXTERA ENERGY INC 146.159.473 US9113121068 US UNITED PARCEL SERVICE-CL B 144.487.870 US0367521038 US ANTHEM INC 144.231.447 NL0000395903 NL WOLTERS KLUWER 143.362.427 US0382221051 US APPLIED MATERIALS INC 143.182.281 GB00B19NLV48 GB EXPERIAN PLC 142.447.328 GB00BNTJ3546 NL ALLFUNDS GROUP PLC 141.314.056 US6541061031 US NIKE INC -CL B 139.470.796 US0533321024 US AUTOZONE INC 138.489.097 US7475251036 US QUALCOMM INC 138.477.157 DK0060634707 DK ROYAL UNIBREW 137.816.910 US5486611073 US LOWE'S COS INC 136.739.802 US11135F1012 US BROADCOM INC 135.801.121 DE0005552004 DE DEUTSCHE POST AG-REG 135.457.195 US07725L1026 US BEIGENE LTD-ADR 134.867.988 JP3496400007 JP KDDI CORP 134.851.374 KYG596691041 HK MEITUAN-CLASS B 134.390.699 US6174464486 US MORGAN STANLEY 134.288.832 US9497461015 US WELLS FARGO & CO 134.234.727 US94106L1098 US WASTE MANAGEMENT INC 133.604.337 US2358511028 US DANAHER CORP 129.989.935 US5801351017 US MCDONALD'S CORP 129.680.708 DK0060952919 DK NETCOMPANY GROUP AS 128.389.027 DE0007236101 DE SIEMENS AG-REG 127.245.657 DE000ZAL1111 DE ZALANDO SE 126.323.585 US90353T1007 US UBER TECHNOLOGIES INC 125.523.490 GB0002074580 GB GENUS PLC 124.709.969 IE00BZ12WP82 US LINDE PLC 122.095.900 GB0009895292 GB ASTRAZENECA PLC 121.957.515 US50540R4092 US LABORATORY CRP OF AMER HLDGS 120.941.764 JP3435000009 JP SONY GROUP CORP 118.405.705 CA82509L1076 CA SHOPIFY INC - CLASS A 117.946.918 FI4000297767 SE NORDEA BANK ABP 116.160.979 US38141G1040 US GOLDMAN SACHS GROUP INC 115.567.830 DK0010287663 DK NKT A/S 115.365.409 US7594701077 GB RELIANCE INDS-SPONS GDR 144A 114.677.857 GB0009252882 GB GLAXOSMITHKLINE PLC 114.402.499 GB00BBG9VN75 GB AVEVA GROUP PLC 113.158.202 FR0000051807 FR TELEPERFORMANCE 112.423.466 US7181721090 US PHILIP MORRIS INTERNATIONAL 112.038.272 US28176E1082 US EDWARDS LIFESCIENCES CORP 111.670.548 CH0418792922 CH SIKA AG-REG 111.295.383 US3755581036 US GILEAD SCIENCES INC 111.129.977 DK0060336014 DK NOVOZYMES A/S-B SHARES 109.696.098 CH0024608827 CH PARTNERS GROUP HOLDING AG 108.085.773 US8552441094 US STARBUCKS CORP 107.711.577 US9078181081 US UNION PACIFIC CORP 107.698.959 DE0007164600 DE SAP SE 106.675.615 US6092071058 US MONDELEZ INTERNATIONAL INC-A 105.890.413 US5010441013 US KROGER CO 105.844.992 NL0011794037 NL KONINKLIJKE AHOLD DELHAIZE N 105.598.259 US40412C1018 US HCA HEALTHCARE INC 105.572.009 DK0010244425 DK AP MOLLER-MAERSK A/S-A 105.567.495 US4567881085 US INFOSYS LTD-SP ADR 105.090.990 FR0000120271 FR TOTALENERGIES SE 104.581.112 US0200021014 US ALLSTATE CORP 104.431.590 US3377381088 US FISERV INC 104.417.409 SE0011166610 SE ATLAS COPCO AB-A SHS 104.383.173 DE0005557508 DE DEUTSCHE TELEKOM AG-REG 104.252.841 CH0012453913 CH TEMENOS AG - REG 103.903.597 US6792951054 US OKTA INC 103.898.414 CA8911605092 CA TORONTO-DOMINION BANK 102.842.974 US4612021034 US INTUIT INC 101.170.319 US88579Y1010 US 3M CO 100.948.962 DK0060027142 DK ALK-ABELLO A/S 100.413.999 US09247X1019 US BLACKROCK INC 99.447.533 NL0013654783 NL PROSUS NV 98.847.573 FR0010307819 FR LEGRAND SA 98.512.846 SE0007100581 SE ASSA ABLOY AB-B 96.692.097 AU000000CBA7 AU COMMONWEALTH BANK OF AUSTRAL 96.492.996 FR0000125486 FR VINCI SA 95.512.903 US29414B1044 US EPAM SYSTEMS INC 95.465.451 DK0010274844 DK SOLAR A/S-B SHS 95.090.567 US90184D1000 US TWIST BIOSCIENCE CORP 95.019.713 US74834L1008 US QUEST DIAGNOSTICS INC 94.604.440 FR0000121261 FR MICHELIN (CGDE) 93.208.724 US0258161092 US AMERICAN EXPRESS CO 92.664.225 JP3756600007 JP NINTENDO CO LTD 91.310.790 GB00BJDQQ870 GB WATCHES OF SWITZERLAND GROUP 90.857.129 IE0004927939 IE KINGSPAN GROUP PLC 90.777.789 US5128071082 US LAM RESEARCH CORP 90.702.394 US2566771059 US DOLLAR GENERAL CORP 89.885.053 US37045V1008 US GENERAL MOTORS CO 87.933.971 IT0005366767 IT NEXI SPA 87.925.846 DE0008404005 DE ALLIANZ SE-REG 87.856.478 US3696041033 US GENERAL ELECTRIC CO 87.585.454 GB00BN3ZZ526 GB VOLUTION GROUP PLC 87.104.691 DE0007100000 DE DAIMLER AG-REGISTERED SHARES 86.801.752 AU000000WES1 AU WESFARMERS LTD 86.008.657 US03027X1000 US AMERICAN TOWER CORP 85.950.496 US2855121099 US ELECTRONIC ARTS INC 85.491.757 GB0005405286 GB HSBC HOLDINGS PLC 85.316.150 GB00B0SWJX34 GB LONDON STOCK EXCHANGE GROUP 85.101.627 GB0002374006 GB DIAGEO PLC 84.445.527 FR0000120321 FR L'OREAL 84.354.193 NL0015435975 IT DAVIDE CAMPARI-MILANO NV 84.353.259 KY30744W1070 US FARFETCH LTD-CLASS A 83.859.968 FR0014000MR3 FR EUROFINS SCIENTIFIC 83.578.417 US48123V1026 US J2 GLOBAL INC 83.370.444 DK0010219153 DK ROCKWOOL INTL A/S-B SHS 83.201.295 US1491231015 US CATERPILLAR INC 83.044.867 DK0060738599 DK DEMANT A/S 82.976.253 GB00BF16C058 GB ALPHA FINANCIAL MARKETS CONS 82.868.211 JP3818000006 JP FUJITSU LTD 82.829.893 DK0060227585 DK CHR HANSEN HOLDING A/S 82.260.007 US7607591002 US REPUBLIC SERVICES INC 81.942.082 US0079031078 US ADVANCED MICRO DEVICES 81.579.243 CH0435377954
Load more

Recommended publications
  • Blackrock UK Smaller Companies PDF Factsheet
    Adventurous 31 August 2021 Life Fund SW BlackRock UK Smaller Companies Life Asset Allocation (as at 31/07/2021) This document is provided for the purpose of UK Small Cap Companies 99.8% information only. This factsheet is intended for individuals who are familiar with investment Money Market 0.2% terminology. Please contact your financial adviser if you need an explanation of the terms used. This material should not be relied upon as sufficient information to support an investment decision. The portfolio data on this factsheet is updated on a quarterly basis. Fund Aim The fund aims for long-term growth by investing in UK smaller companies which the Fund Manager considers to have above average long-term growth prospects. The fund Sector Breakdown (as at 31/07/2021) invests solely through the BlackRock UK Consumer Discretionary 27.7% Smaller Companies Unit Trust. Industrials 25.1% Basic Fund Information Financials 12.2% Fund Launch Date 19/09/2001 Technology 11.3% Fund Size £5.3m Basic Materials 5.1% Sector ABI UK Smaller Other 4.9% Companies Energy 3.8% ISIN GB0030873565 Consumer Staples 3.8% MEX ID SWMUL Health Care 3.7% SEDOL 3087356 Telecommunications 2.5% Manager Name Roland Arnold Regional Breakdown (as at 31/07/2021) Manager Since 26/03/2015 Top Ten Holdings (as at 31/07/2021) WATCHES OF SWITZERLAND 2.9% GROUP PLC IMPAX ASSET MANAGEMENT 2.4% GROUP PLC TREATT PLC 2.2% The composition of asset mix and asset allocation may change at any time and exclude cash CVS GROUP PLC 2.1% unless otherwise stated BREEDON GROUP PLC 2.0% OXFORD INSTRUMENTS PLC 1.8% INTEGRAFIN HOLDINGS PLC 1.8% AUCTION TECHNOLOGY GROUP 1.7% PLC ERGOMED PLC 1.7% LEARNING TECHNOLOGIES GROUP 1.7% PL TOTAL 20.3% Page 1 Past Performance Fund Rating Information 100% Overall Morningstar **** Rating Morningstar Analyst Rating 50% FE fundinfo Crown Rating The FE fundinfo Crown Rating relates to this fund.
    [Show full text]
  • Case 15-11663-LSS Doc 212 Filed 10/12/15 Page 1 of 109 Case 15-11663-LSS Doc 212 Filed 10/12/15 Page 2 of 109
    Case 15-11663-LSS Doc 212 Filed 10/12/15 Page 1 of 109 Case 15-11663-LSS Doc 212 Filed 10/12/15 Page 2 of 109 EXHIBIT A Response Genetics, Inc. - U.S. CaseMail 15-11663-LSS Doc 212 Filed 10/12/15 Page 3 of 109 Served 10/9/2015 12 WEST CAPITAL MANAGEMENT LP 1727 JFK REALTY LP 3S CORPORATION 90 PARK AVENUE, 41ST FLOOR A PARTNERSHIP 1251 E. WALNUT NEW YORK, NY 10016 1727 JFK REALTY LLC CARSON, CA 90746 100 ENGLE ST CRESSKILL, NJ 07626-2269 4281900 CANADA INC. A C PHILLIPS AAAGENT SERVICES, LLC ATTN: DEBORAH DOLMAN 2307 CRESTVIEW ST 125 LOCUST ST. 100 RUE MARIE-CURIE THE VILLAGES, FL 32162-3455 HARRISBURG, PA 17101 DOLLARD-DES-ORMEAUX, QC H9A 3C6 CANADA AARON D SUMMERS AARON K BROTEN IRA TD AMERITRADE AARON WANG 202 S SUNNY SLOPE ST CLEARING CUSTODIAN 6880 SW 44TH ST #215 W FRANKFORT, IL 62896-3104 1820 PLYMOUTH LN UNIT 2 MIAMI, FL 33155-4765 CHANHASSEN, MN 55317-4837 AASHISH WAGLE ABBOTT MOLECULAR INC. ABBOTT MOLECULAR INC. 2220 W MISSION LN APT 1222 1300 EAST TOUHY AVENUE 75 REMITTANCE DRIVE SUTIE 6809 PHOENIX, AZ 85021 DES PLAINES, IL 60068 CHICAGO, IL 60675-6809 ABBOTT MOLECULAR INC. ABDUL BASIT BUTT ABE OFFICE FURNITURE OUTLET DIVISION COUNSEL 14 RENOIR DRIVE 3400 N. PECK RD. 1350 E. TOUHY AVE., STE 300W MONMOUTH JUNCTION, NJ 08852 EL MONTE, CA 91731 DES PLAINES, IL 60018 ABEDIN JAMAL ABEY M GEORGE ABHIJIT D NAIK 9253 REGENTS RD UNIT A207 3206 LOCHAVEN DR 1049 W OGDEN AVE LA JOLLA, CA 92037-9161 ROWLETT, TX 75088 APT 103 NAPERVILLE, IL 60563 ABRAHAM BROWN ACCENT - 1 ACCENT - 2 DESIGNATED BENE PLAN/TOD P.O.
    [Show full text]
  • Portfolio Holdings Listing Fidelity Advisor Asset Manager 40% As Of
    Portfolio Holdings Listing Fidelity Advisor Asset Manager 40% DUMMY as of July 30, 2021 The portfolio holdings listing (listing) provides information on a fund’s investments as of the date indicated. Top 10 holdings information (top 10 holdings) is also provided for certain equity and high income funds. The listing and top 10 holdings are not part of a fund’s annual/semiannual report or Form N-Q and have not been audited. The information provided in this listing and top 10 holdings may differ from a fund’s holdings disclosed in its annual/semiannual report and Form N-Q as follows, where applicable: With certain exceptions, the listing and top 10 holdings provide information on the direct holdings of a fund as well as a fund’s pro rata share of any securities and other investments held indirectly through investment in underlying non- money market Fidelity Central Funds. A fund’s pro rata share of the underlying holdings of any investment in high income and floating rate central funds is provided at a fund’s fiscal quarter end. For certain funds, direct holdings in high income or convertible securities are presented at a fund’s fiscal quarter end and are presented collectively for other periods. For the annual/semiannual report, a fund’s investments include trades executed through the end of the last business day of the period. This listing and the top 10 holdings include trades executed through the end of the prior business day. The listing includes any investment in derivative instruments, and excludes the value of any cash collateral held for securities on loan and a fund’s net other assets.
    [Show full text]
  • EP Vantage Interview - Silence Hoping to Have Something to Shout About in 2009
    December 22, 2008 EP Vantage Interview - Silence hoping to have something to shout about in 2009 Lisa Urquhart With its first product expected to go into the clinic potentially as early as January, Silence Therapeutics is hoping that 2009 will be year it has something to shout about and one that will reverse the alarming share price decline that has seen the company’s valuation slip from a high of over £170m in June 2007 to £21.6m today. Silence is one of a growing number of companies working in RNA interference (RNAi) and particularly short interfering RNA (siRNA), which work by selectively silencing or inactivating genes related to certain diseases. It is importantly one of only two companies that have composition of matter patent protection for their siRNA drugs. Speaking to EP Vantage, Iain Ross, chief executive of Silence, says: “It’s a big year coming up for us.” The group has spent most of the last 12 months strengthening its IP position, and next year comes the important move of the group’s lead candidate Atu027 into the clinic, an event Mr Ross says should take place in the first quarter of the year. Many expect it could be as soon as the end of January. Partnering focus What is less expected is the speed at which Mr Ross intends to partner the drug, which is being developed in solid tumours, with an emphasis on lung cancer. “We would be looking at doing something either at the end of 2009 or the beginning of 2010,” he says. Key to partnering discussions will be the drug demonstrating good safety data in a number of cancer patients, which could be the catalyst to starting talks with big pharma who have already started to ask about Atu027.
    [Show full text]
  • IQVIA Pharma Deals Half-Year Review of 2020
    White Paper IQVIA Pharma Deals Half-Year Review of 2020 HEATHER CARTWRIGHT, Senior Analyst, Global Market Insights, IQVIA MICHELLE LIU, Analyst, Global Market Insights, IQVIA TASKIN AHMED, Manager, Global Market Insights, IQVIA Table of contents Introduction 1 Uncertainty and prudence cause M&A to stall 2 Licensing deal values continue to rise 5 Roche pips AstraZeneca to title of most active dealmaker 10 COVID-19 pandemic drives increase in R&D collaboration 11 Infectious diseases replace oncology as top therapeutic area for dealmaking 14 Outlook for H2 2020 15 About the authors 17 Introduction COVID-19 shakes up the dealmaking landscape H1 2020 was an unprecedented time for dealmaking in the life sciences sector. While the COVID-19 pandemic rapidly provoked a significant level of partnering activity amongst biopharma companies keen to expedite the development of vaccines or therapeutics to tackle the virus, it also acted as a brake on other types of dealmaking, most notably M&A which saw a sharp decline in activity as a result of uncertainty and operational disruption. Indeed, H1 2020 was notable for the absence of any US$5 B deals on the scale seen in previous years as companies instead focused their attentions on internal programs and potential COVID-19 solutions, opting only for a few asset-driven acquisitions. There was also plentiful capital available to allow biotech companies to stay independent, particularly those in the US. As a result, aggregate spending on M&A by life science companies plummeted to just US$19.1 B in the first 6 months of 2020.
    [Show full text]
  • RETAIL BANKING Americas DIGEST
    Financial Services VOLUME III – SUMMER 2013 RETAIL BANKING AMERICAS DIGEST IN THIS ISSUE 1. SMALL BUSINESS BANKING Challenging Conventional Wisdom to Achieve Outsize Growth and Profitability 2. FINANCING SMALL BUSINESSES How “New-Form Lending” Will Reshape Banks’ Small Business Strategies 3. ENHANCED PERFORMANCE MANAGEMENT Driving Breakthrough Productivity in Retail Banking Operations 4. INNOVatION IN MORtgagE OPERatIONS Building a Scalable Model 5. CHASE MERCHANT SERVICES How Will it Disrupt the Card Payments Balance of Power? 6. THE FUTURE “AR Nu” What We Can Learn from Sweden About the Future of Retail Distribution FOREWORD Banking is highly regulated, intensely competitive and provides products that, while omnipresent in consumers’ lives, are neither top-of-mind nor enticing to change. These factors drive the role and form of innovation the industry can capitalize on. In traditional business history – the realm of auto manufacturers, microchip makers, logistics companies and retailers – the literature rightly hails disruptive, game-changing innovation as the engine behind outsized profits for the first movers. In banking, such innovation is very rare. Disruptive innovations of the magnitude of the smartphone or social networking grab headlines, but are hard to leverage in the banking industry. There are simply too many restrictions on what banks can do, and too much consumer path dependency, to place all the shareholders’ chips on disruptive innovation plays. Instead, successful banks develop and execute strategies around less “flashy”,
    [Show full text]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
    [Show full text]
  • SA FUNDS INVESTMENT TRUST Form N-Q Filed 2016-11-23
    SECURITIES AND EXCHANGE COMMISSION FORM N-Q Quarterly schedule of portfolio holdings of registered management investment company filed on Form N-Q Filing Date: 2016-11-23 | Period of Report: 2016-09-30 SEC Accession No. 0001206774-16-007593 (HTML Version on secdatabase.com) FILER SA FUNDS INVESTMENT TRUST Mailing Address Business Address 10 ALMADEN BLVD, 15TH 10 ALMADEN BLVD, 15TH CIK:1075065| IRS No.: 770216379 | State of Incorp.:DE | Fiscal Year End: 0630 FLOOR FLOOR Type: N-Q | Act: 40 | File No.: 811-09195 | Film No.: 162016544 SAN JOSE CA 95113 SAN JOSE CA 95113 (800) 366-7266 Copyright © 2016 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-09195 SA FUNDS - INVESTMENT TRUST (Exact name of registrant as specified in charter) 10 Almaden Blvd., 15th Floor, San Jose, CA 95113 (Address of principal executive offices) (Zip Code) Deborah Djeu Chief Compliance Officer SA Funds - Investment Trust 10 Almaden Blvd., 15th Floor, San Jose, CA 95113 (Name and Address of Agent for Service) Copies to: Brian F. Link Mark D. Perlow, Esq. Vice President and Managing Counsel Counsel to the Trust State Street Bank and Trust Company Dechert LLP 100 Summer Street One Bush Street, Suite 1600 7th Floor, Mailstop SUM 0703 San Francisco, CA 94104-4446 Boston, MA 02111 Registrants telephone number, including area code: (800) 366-7266 Date of fiscal year end: June 30 Date of reporting period: September 30, 2016 Copyright © 2013 www.secdatabase.com.
    [Show full text]
  • Reduction in the Risk of Major Adverse Cardiovascular Events
    Reduction in the Risk of Major Adverse Cardiovascular Events with Apabetalone, a BET Protein Inhibitor, in Patients with Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the BETonMACE Trial Gregory G. Schwartz1, Stephen J. Nicholls2, Henry N. Ginsberg3, Jan O. Johansson4, Kamyar Kalantar‐Zadeh5, Ewelina Kulikowski4, Peter P Toth6, Norman Wong4, Michael Sweeney4, Kausik K Ray7 On behalf of the BETonMACE Investigators 1Division of Cardiology, University of Colorado School of Medicine, Aurora, CO USA; 2Monash University Cardiovascular Research Center, Melbourne, Australia; 3Vagelos College of Physicians and Surgeons, Columbia University, New York, NY USA; 4Resverlogix Corp., Calgary, Alberta, Canada; 5University of California Irvine School of Medicine, Orange, CA USA; 6CGH Medical Center, Sterling, IL and Johns Hopkins University, Baltimore, MD USA; 7Imperial College Center for Cardiovascular Disease Prevention, London UK American Heart Association – 2020 Scientific Sessions November 2020 ClinicalTrials.gov: NCT02586155 Disclosures • The BETonMACE trial was funded by Resverlogix • Dr Schwartz reports research grants to the University of Colorado from Resverlogix, Sanofi, The Medicines Company, and Roche; and is coinventor of pending US patent 14/657192 (“Methods of Reducing Cardiovascular Risk”) assigned in full to the University of Colorado. • Dr. Nicholls reports grants from Resverlogix, during the conduct of the study; grants and personal fees from AstraZeneca, grants and personal fees from
    [Show full text]
  • Unlocking the Potential of Gene Silencing for Everyone
    Corporate Presentation JP Morgan Conference January 2018 Forward looking statements The information contained in this presentation is being supplied and communicated to you on a Securities in the Company have not been, and will not be, registered under the United States confidential basis solely for your information and may not be reproduced, further distributed to Securities Act of 1933, as amended (the “Securities Act”), or qualified for sale under the law of any other person or published, in whole or in part, for any purpose. In accordance with the any state or other jurisdiction of the United States of America and may not be offered or sold in prohibition on market abuse contained in Part VIII of the Financial Services and Markets Act the United States of America except pursuant to an exemption from, or in a transaction not 2000 (as amended) (the “Act”): (i) you must not pass this information to any person; and (ii) subject to, the registration requirements of the Securities Act. Neither the United States you must not base any behaviour in relation to any securities or other Qualifying Investments Securities and Exchange Commission nor any securities regulatory body of any state or other (as that term is defined in the Act) which would amount to market abuse on such information jurisdiction of the United States of America, nor any securities regulatory body of any other until after it is made generally available. country or political subdivision thereof, has approved or disapproved of this presentation or the securities discussed herein or passed on the accuracy or adequacy of the contents of this This presentation is being communicated in the United Kingdom only to (a) persons who have presentation.
    [Show full text]
  • GSK's Big Reveal
    3 August 2018 No. 3916 Scripscrip.pharmaintelligence.informa.com Pharma intelligence | informa at Genentech Inc. (Also see “GSK Bags Bar- ron As R&D Boss As Vallance Joins UK Govern- ment” - Scrip, 8 Nov, 2017.) With a budding early immuno-oncology pipeline, Walmsley clearly has her eye on establishing GSK as an important player in the space. The event in London was Barron’s first op- portunity to present his R&D strategy and coincided with the company’s second quar- ter sales and earnings release. “This is an ideal time to be thinking about reinventing R&D, because we are doing well. We are growing,” Barron said. PILLARS FOR INNOVATION Investors have been eager to hear from the R&D legend, but with few near-term catalysts or big changes to the late-stage pipeline, they may be underwhelmed by the update. Barron, meanwhile, is focused on deliver- GSK’s Big Reveal: ing scientific and cultural changes that will yield breakthroughs over the long-term. An R&D Overhaul Poised To Yield He talked about a time horizon of 2021 to 2026, and he talked more high-level, rather than specifics, about incentives needed to Long-Term Cultural Change drive innovation, the technologies that can JESSICA MERRILL [email protected] help improve clinical trial success, and cul- tural changes. He said science, technology laxoSmithKline PLC CEO Emma pharma R&D – is that investors will need to and culture are the three pillars needed to Walmsley may have spelled out the be patient to see GSK deliver on its promise drive innovation, and all three must be in Gbig pharma’s R&D turnaround plan of innovation.
    [Show full text]
  • FTSE Russell Publications
    2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore
    [Show full text]